Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 8:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Thromboprophylaxis Clear all
Recruiting Not applicable Interventional

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

NCT07613840
View directory record Official record
Conditions
Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis), Platelet Aggregation Inhibitors, Thromboelastography (TEG), PRU(Platelet Reactivity Unit)
Interventions
Aspirin, Clopidogrel, Ticagrelor, Rivaroxaban, Thromboelastography with Platelet Mapping
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Salem, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 26, 2026, 8:12 PM EDT
Completed Phase 2 Interventional Results available

Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy

NCT02366871
View directory record Official record
Conditions
Gynecologic Cancer, Venous Thromboembolism
Interventions
Oral apixaban, Subcutaneous enoxaparin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Los Angeles, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 26, 2026, 8:12 PM EDT
Not listed Not applicable Interventional

Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism

NCT06232551
View directory record Official record
Conditions
Venous Thromboembolic Disease, Pulmonary Embolism and Thrombosis, Deep Vein Thrombosis, Hospitalism
Interventions
EHR (electronic health record) alert, No EHR (electronic health record) alert
Other
Lead sponsor
Scott C. Woller, MD
Other
Eligibility
18 Years to 110 Years
Enrollment
152,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 26, 2026, 8:12 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)

NCT03532139
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Enoxaparin, Enoxaparin + Rosuvastatin, Thromboprophylaxis
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 26, 2026, 8:12 PM EDT
Completed Phase 3 Interventional Results available

COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis

NCT04650087
View directory record Official record
Conditions
Covid19
Interventions
Apixaban 2.5 MG, Placebo
Drug
Lead sponsor
Thomas L. Ortel
Other
Eligibility
18 Years and older
Enrollment
1,291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
121
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 101 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 26, 2026, 8:12 PM EDT
Not yet recruiting Phase 4 Interventional

Extended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease

NCT07713875
View directory record Official record
Conditions
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Spine Metastasis
Interventions
Apixaban
Drug
Lead sponsor
James Bayley
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Pittburgh, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 26, 2026, 8:12 PM EDT
Enrolling by invitation Phase 2 Interventional

Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism

NCT05794165
View directory record Official record
Conditions
Trauma Injury, Thromboembolism, Venous Thromboembolism
Interventions
Thrombate infusion, Placebo
Drug
Lead sponsor
Bryan Cotton
Other
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Aurora, Colorado • Miami, Florida • Jackson, Mississippi + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 26, 2026, 8:12 PM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 26, 2026, 8:12 PM EDT
Completed Phase 3 Interventional Results available

Prospective Study on Preoperative Versus Postoperative Venous Thromboprophylaxis in Patients Undergoing Major Colorectal Surgery

NCT01976988
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Heparin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2016 · Synced Oct 26, 2026, 8:12 PM EDT
Recruiting Not applicable Interventional

AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial.

NCT06939803
View directory record Official record
Conditions
Venothromboembolism
Interventions
Risk model-driven CDS
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Not listed
Enrollment
2,236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 26, 2026, 8:12 PM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery

NCT00709904
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Open-label Semuloparin sodium, Placebo (for Semuloparin sodium), Semuloparin sodium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2013 · Synced Oct 26, 2026, 8:12 PM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure

NCT02846532
View directory record Official record
Conditions
Thrombosis
Interventions
Rivaroxaban, Acetylsalicylic Acid
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 8 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
17
States / cities
Los Angeles, California • Gainesville, Florida • Oak Lawn, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 26, 2026, 8:12 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

A Comparison of Sequential Compression Devices and Foot Pumps in the Obstetric Population

NCT00356434
View directory record Official record
Conditions
Thrombophilia
Interventions
Kendall A-V foot impulse pump, model 6060, Kendall sequential compression device, model 9525
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 26, 2026, 8:12 PM EDT
Completed Not applicable Interventional Results available

The Angel® Catheter Pivotal Clinical Trial

NCT02186223
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism, Trauma
Interventions
The Angel® Catheter
Device
Lead sponsor
BiO2 Medical
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
21
States / cities
Los Angeles, California • San Diego, California • Loveland, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 26, 2026, 8:12 PM EDT
Completed Not applicable Interventional Results available

Prospective Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin (Coumadin)

NCT00634907
View directory record Official record
Conditions
Venous Thromboembolism, Bleeding
Interventions
Pharmacogenetic-based warfarin dosing, Usual care warfarin dosing
Genetic · Other
Lead sponsor
Gwen McMillin
Other
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 26, 2026, 8:12 PM EDT
Completed Phase 4 Interventional

Apixaban vs Rivaroxaban vs No Anticoagulant to Prevent EHIT After Great Saphenous Vein Laser Ablation

NCT07699796
View directory record Official record
Conditions
Venous Thrombosis Deep (Limbs), Venous Insufficiency (Chronic)(Peripheral), Varicose Veins Leg, Venous Thrombosis
Interventions
Apixaban, Rivaroxaban
Drug
Lead sponsor
Heart, Artery, and Vein Center of Fresno
Other
Eligibility
18 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 26, 2026, 8:12 PM EDT
Terminated Phase 4 Interventional Results available

Aspirin and Enoxaparin for VTE in Trauma

NCT02396732
View directory record Official record
Conditions
Venous Thromboembolism, Thromboprophylaxis, Trauma
Interventions
Aspirin, Enoxaparin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 26, 2026, 8:12 PM EDT
Active, not recruiting Not applicable Interventional

Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization

NCT07597239
View directory record Official record
Conditions
Thrombosis, Arterial Occlusive Diseases, Thromboelastography (TEG), Peripheral Arterial Disease(PAD), Stent Thrombosis, Platelet Inhibition, PRU(Platelet Reactivity Unit)
Interventions
Aspirin, Clopidogrel, Ticagrelor, Platelet Reactivity Testing, Thromboelastography with Platelet Mapping
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 26, 2026, 8:12 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Low-Molecular-Weight Heparin (LMWH) for Deep Venous Thrombosis (DVT) Prophylaxis

NCT01029821
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Low-Molecular-Weight Heparin
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Oct 26, 2026, 8:12 PM EDT
Enrolling by invitation Not applicable Interventional

Implementing VTE Prevention in Ambulatory Cancer Care

NCT07292376
View directory record Official record
Conditions
Venous Thromboembolism, Neoplasms
Interventions
Clinical program
Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 26, 2026, 8:12 PM EDT
Terminated Phase 2 Interventional Results available

Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Trial

NCT03003390
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Enoxaparin
Drug
Lead sponsor
Yale University
Other
Eligibility
Up to 17 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
New Haven, Connecticut • St Louis, Missouri • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 26, 2026, 8:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparing Anti-XA Levels in Post-Cesarean Patients Undergoing Enoxaparin Thromboprophylaxis

NCT02070237
View directory record Official record
Conditions
Obesity, Obesity, Morbid, Pregnancy, Complications; Cesarean Section, Venous Thromboembolism, Postpartum Deep Phlebothrombosis, Pulmonary Embolism
Interventions
Enoxaparin
Drug
Lead sponsor
MemorialCare Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Oct 26, 2026, 8:12 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study

NCT07215624
View directory record Official record
Conditions
Malignant Digestive System Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Genitourinary System Neoplasm
Interventions
Non-Interventional Study
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
102
States / cities
Kingman, Arizona • Fort Smith, Arkansas • Oakland, California + 81 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 26, 2026, 8:12 PM EDT
Completed Phase 4 Interventional Results available

Covid-19 Associated Coagulopathy

NCT04360824
View directory record Official record
Conditions
COVID 19 Associated Coagulopathy
Interventions
Intermediate dose thromboprophylaxis, Standard of Care thromboprophylaxis
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 100 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Iowa City, Iowa • La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 26, 2026, 8:12 PM EDT